Veeva Systems delivered a sturdy QQ4 2026 performance characterized by durable top-line growth and one of the highest operating margins in the healthcare cloud software space. Revenue totaled $835.95 million for the quarter, up 15.96% year over year and 3.05% quarter over quarter, reflecting sustained demand for Veeva’s cloud-based solutions across the life sciences ecosystem. Gross margin remained exceptionally healthy at 74.46%, underpinning operating profitability with an operating income of $245.88 million and an EBITDA of $245.88 million (margin ≈ 29.4%). Net income reached $244.20 million, delivering a net margin of 29.21% and basic/diluted EPS of $1.49/$1.45 respectively.
The balance sheet remains exceptionally cash-rich, with cash and short-term investments totaling $6.56 billion and net debt of about negative $1.33 billion. Deferred revenue stood at $1.49 billion on the balance sheet, signaling a strong pipeline and revenue visibility from ongoing subscriptions and long-term contracts. Operating cash flow was $106.85 million, supporting free cash flow of the same magnitude and enabling meaningful capital allocation activity, including roughly $169.95 million of share repurchases and $13.87 million of stock issuances, while there were no disclosed cash dividends. Management commentary (when available) typically emphasizes continued expansion in core platforms (CRM, Vault/Data Cloud) and the stickiness of Veeva’s vertical SaaS, which should support continued margin expansion and durable cash generation over the medium term. Given the favorable margin profile, robust balance sheet, and steady growth trajectory, the investment thesis centers on the enduring demand for cloud-based life sciences software and the potential for further cross-sell and up-sell within existing customer bases.